PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (NCT04015622)
A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction \<2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post abiraterone setting.
Who can join: Review the eligibility criteria below.
Location: BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre) — Kelowna, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre) — Kelowna, British Columbia
- BC Cancer - Centre for the North — Prince George, British Columbia
- BC Cancer - Surrey Centre — Surrey, British Columbia
- Sunnybrook Health Sciences Centre — Toronto, British Columbia
- BC Cancer - Vancouver Centre — Vancouver, British Columbia
- BC Cancer - Victoria Centre — Victoria, British Columbia
- London Health Sciences Centre — London, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer — Anchorage, Alaska
- Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer — Oklahoma City, Oklahoma
- Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function — New York, New York
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T — Tuscon, Arizona
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors — Gilbert, Arizona
Explore by condition: All Metastatic Castration-Resistant Prostate Cancer (mCRPC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.